Partnership--Moffitt Cancer--Puerto Rico Cancer Center

H.李·莫菲特癌症中心（HLMCC）和波多黎各癌症中心（PRCC）在过去一年中一直在进行合作，并最终共同签署了一项附属协议。坦帕和圣胡安在地理上的接近使得这种伙伴关系顺理成章。 此外，这些机构中的每一个都有需要进一步发展的领域，这种特殊的机构伙伴关系提供了促进这种发展的专门知识。 HLMCC服务于由一个重要的西班牙裔社区组成的人口。 西班牙裔在癌症护理方面服务不足，因此，HLMCC致力于提高其向佛罗里达西班牙裔社区提供癌症护理的能力。 从PRCC获得的专业知识将有助于实现这一目标，开发一个旨在开发针对西班牙裔社区的外展和癌症教育计划的项目。 PRCC在临床研究中很活跃;然而，他们还没有能力进行早期化疗试验和转化研究。 HLMCC在这些领域拥有专门知识，将与PRCC分享。 将设立的具体计划将包括为医学肿瘤学和血液学研究员提供临床、转化研究方面的培训计划。此外，还将为外科肿瘤学家设立淋巴映射和前哨淋巴结活检技术的培训计划。 PRCC进行这些临床试验的能力增强将导致参与此类临床研究的西班牙裔医生数量增加，并将提高西班牙裔患者在临床试验中的代表性。 为了开发专门针对西班牙裔人群的未来转化研究，将开发一个基础研究项目，旨在鉴定西班牙裔癌症患者肿瘤中致癌途径的分子畸变。

The development of a partnership between the H. lee Moffitt Cancer Center (HLMCC) and the Puerto Rico Cancer Center (PRCC) has been in progress over the past year and has resulted in the joint signing of an affiliation agreement. The close geographic proximity of Tampa and San Juan made this partnership logical. In addition, each of these institutions has areas where further development is necessary, and this particular institutional partnership provides expertise to enhance this development. The HLMCC serves a population that consists of a significantg Hispanic community. Hispanics are underserved with respect to cancer care, and therefore, the HLMCC is committed to improving its ability to deliver cancer care to the Hispanic community in Florida. Expertise obtained from the PRCC will help to accomplish this goal, with the development of a project designed to develop outreach and cancer education programs which target the Hispanic community. The PRCC is active in clinical research; however, they have not yet had the capacity to perform early phase chemotherapy trials and translational research. The HLMCC has expertise in these areas which will be shared with the PRCC. The specific programs that will be set up will include a training program in clinical, translational research for medical oncology and hematology fellows. Additionally, a training program for surgical oncologists will be set up in the technique of lymphatic mapping and sentinel lymph node biopsy. An enhanced capacity of the PRCC to conduct these clinical trials will result in an increase in the number of Hispanic physicians participating in such clinical research, and will enhance the representation of Hispanic patients in clinical trials. In order to develop future translational research specifically targeting the Hispanic population, a basic research project will be developed designed to identify molecular aberrations in oncogenic pathways in tumors from Hispanic cancer patients.